Description de l'entreprise
Novavax, Inc. is an American biotechnology company headquartered in Gaithersburg, Maryland. Their mission is to address serious infectious diseases globally through the discovery and development of innovative vaccines. They focus on creating life-saving vaccines using solid science that has been tested through decades of research. Prior to 2020, Novavax scientists developed experimental vaccines for influenza, respiratory syncytial virus (RSV), Ebola, and other emerging infectious diseases. The company engages in the discovery, development, and commercialization of recombinant vaccines
Conseil d'administration & Conseil de surveillance
| PDG |
| John C. Jacobs |
| Conseil d'administration |
| Jim Kelly, John J. Trizzino, Mark Casey, Rick Crowley, Elaine O’Hara, Silvia Taylor, Ian Watkins, Troy Morgan, Robert Walker |
| Conseil de surveillance |
| James F. Young, Gregg Alton, Richard Douglas, Rachel King, Margaret G. McGlynn, David Mott, Rick Rodgers |
Données de l'entreprise
| Nom: |
Novavax Inc. |
| Adresse: |
21 Firstfield Rd,Gaithersburg |
| Téléphone: |
+1-240-2682000 |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
https://global.novavax.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
94.12% |
| IPO date: |
05/12/1995 |
Relations avec les investisseurs
| Nom: |
Erika Schultz |
| Téléphone IR: |
+1-240-268-2022 |
| IR-Fax: |
- |
| E-mail IR: |
ir@novavax.com
|
